Paper Details

  1. Home
  2. Paper Details

Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.

Author: ChiangChen-Yuan, MadanJason, MeredithSarah K, NunnAndrew J, PhillipsPatrick P J, RusenI D, SquireS Bertel, TorreaGabriela, Van DeunArmand

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

This research highlights the lack of strong evidence-based guidelines for treating multi-drug-resistant tuberculosis (MDR-TB). Current recommendations are based on expert opinion and suggest treatment for at least 20 months. The study proposes a nine-month regimen that showed promising results in cohort studies and calls for randomized controlled trials to compare this regimen with standard treatments, including for patients with HIV co-infection.
Paper Details　
Original Abstract of the Article :
In contrast to drug-sensitive tuberculosis, the guidelines for the treatment of multi-drug-resistant tuberculosis (MDR-TB) have a very poor evidence base; current recommendations, based on expert opinion, are that patients should be treated for a minimum of 20 months. A series of cohort studies cond...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164715/

データ提供：米国国立医学図書館（NLM）

STREAM: A New Regimen for Multi-Drug-Resistant Tuberculosis

Tuberculosis (TB) is a serious infectious disease that continues to plague millions worldwide. Treating multi-drug-resistant TB (MDR-TB) is particularly challenging due to the limited availability of effective treatments and the need for long durations of therapy. This study explores the potential of a shorter nine-month regimen (STREAM) for treating MDR-TB, compared to the standard 20-month regimen. It’s like venturing into a desolate desert landscape, seeking a more efficient and sustainable path to healing.

The STREAM Regimen: A More Efficient Approach

The researchers are conducting a randomized controlled trial to compare the effectiveness of the STREAM regimen to the standard 20-month regimen in various settings, including patients with HIV coinfection. The study aims to determine if the STREAM regimen is as effective as the standard regimen but with a significantly shorter treatment duration. It’s like discovering a shorter and more efficient route through the vast desert, leading to faster and safer arrival at the destination.

Navigating the Desert of TB Treatment

This study highlights the ongoing search for more efficient and effective treatments for MDR-TB. It’s a reminder that even in the face of seemingly insurmountable challenges, like a vast and unforgiving desert, innovative solutions can emerge. The results of this study could have a profound impact on the lives of millions affected by MDR-TB.

Dr. Camel's Conclusion

The STREAM regimen represents a potential breakthrough in MDR-TB treatment, offering a shorter, more efficient path to recovery. It's like discovering a hidden oasis in the vast desert of TB research, providing a much-needed source of hope for those battling this challenging disease.

Date :
  1. Date Completed 2015-05-21
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

25199531

DOI: Digital Object Identifier

PMC4164715

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.